Price Size
$250 50ul
$350 100ul
$450 200ul

Same day delivery

For pricing and ordering contact:

local distributors
  • Product Name
    Vimentin Antibody
  • Catalog No.
  • RRID
  • Source
  • Application
  • Reactivity
    Human, Mouse, Rat
  • Prediction
    Pig, Bovine, Horse, Rabbit, Dog, Chicken, Xenopus
  • UniProt
  • Mol.Wt
  • Concentration
  • Browse similar products>>

Related Products

Product Information

Alternative Names:Expand▼

CTRCT30; Epididymis luminal protein 113; FLJ36605; HEL113; VIM; VIME_HUMAN; Vimentin;


WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:200, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.


Human, Mouse, Rat

Predicted Reactivity:

Pig, Bovine, Horse, Rabbit, Dog, Chicken, Xenopus






The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).


Vimentin Antibody detects endogenous levels of total Vimentin.


Please cite this product as: Affinity Biosciences Cat# AF7013, RRID:AB_2835318.





Storage Condition and Buffer:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl.

Immunogen Information in 3D


A synthesized peptide derived from human Vimentin


>>Visit The Human Protein Atlas

Gene ID:

Gene Name:


Molecular Weight:

Observed Mol.Wt.: 53kD.
Predicted Mol.Wt.: 54kDa(Calculated)..

Subcellular Location:


Tissue Specificity:

Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.


VIM is an intermediate filament protein. Intermediate filament proteins are expressed in a tissue-specific manner. Desmin is the subunit specific for muscle and vimentin the subunit specific for mesenchymal tissue.


Research Background


Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally.

Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.

Post-translational Modifications:

Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin (By similarity). One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm. Phosphorylated by STK33. Phosphorylated on tyrosine residues by SRMS.

O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status.

S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.

Subcellular Location:

Cytoplasm. Cytoplasm>Cytoskeleton. Nucleus matrix.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionGraphics by Christian Stolte

Tissue Specificity:

Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.

Subunit Structure:

Homopolymer assembled from elementary dimers. Interacts with LGSN and SYNM. Interacts (via rod region) with PLEC (via CH 1 domain) (By similarity). Interacts with SLC6A4. Interacts with STK33. Interacts with LARP6. Interacts with RAB8B (By similarity). Interacts with TOR1A; the interaction associates TOR1A with the cytoskeleton. Interacts with TOR1AIP1. Interacts with BCAS3. Interacts with DIAPH1. Identified in complexes that contain VIM, EZR, AHNAK, BFSP1, BFSP2, ANK2, PLEC, PRX and spectrin (By similarity). Interacts with EPPK1; interaction is dependent of higher-order structure of intermediate filament. Interacts with the non-receptor tyrosine kinase SRMS; the interaction leads to phosphorylation of VIM. Interacts with NOD2. Interacts (via head region) with CORO1C (By similarity). Interacts with HDGF (isoform 2).

(Microbial infection) Interacts with HCV core protein.


The central alpha-helical coiled-coil IF rod domain mediates elementary homodimerization.

The [IL]-x-C-x-x-[DE] motif is a proposed target motif for cysteine S-nitrosylation mediated by the iNOS-S100A8/A9 transnitrosylase complex.

Belongs to the intermediate filament family.

Research Fields

Research Fields:

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.
· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

Reference Citations:

1). Xiong J et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell 2020 Mar 16;37(3):403-419 (PubMed: 32183952) [IF=26.602]

Application: IF/ICC    Species:human;    Sample:NK-92 cells

Figure 6. Biological Function of MGA and BRDT. (D) Immunofluorescence images of E-cadherin (green), fibronectin (red), or vimentin (red) in NK-92 cells transfected with MGA shRNAs or scramble. Cells were counterstained with DAPI (blue). (G) Immunofluorescence images of E-cadherin (green), fibronectin (red), or vimentin (red) in NK-92 cells transfected with pCMV6-BRDT (upper panel) or vector control (lower panel). Cells were counterstained with DAPI (blue).

2). Han J et al. YY1 complex promotes Quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma. Cancer Res 2019 Feb 13 (PubMed: 30760518) [IF=9.727]

3). Meng J et al. Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma. Cancer Res 2018 Aug 1;78(15):4150-4162 (PubMed: 29844124) [IF=9.727]

4). Meng J et al. Hsp90β promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma. Oncogene 2018 Aug 7 (PubMed: 30087438) [IF=7.971]

5). Li W;Lu H;Wang H;Ning X;Liu Q;Zhang H;Liu Z;Wang J;Zhao W;Gu Y;Li H;Sun X;Hu L;Wang D; et al. Circular RNA TGFBR2 acts as a ceRNA to suppress nasopharyngeal carcinoma progression by sponging miR-107. Cancer Lett 2021 Feb 28;499:301-313. (PubMed: 33160003) [IF=7.360]

6). Yang L et al. Protopanaxadiol inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by targeting STAT3 pathway. Cell Death Dis 2019 Aug 20;10(9):630 (PubMed: 31431619) [IF=6.304]

7). Wang H et al. Oleanolic acid inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by promoting iNOS dimerization. Mol Cancer Ther 2018 Oct 8 (PubMed: 30297361) [IF=5.615]

8). Zhao W;Hao L;Jia L;Wang J;Wang B;Huang Y;Zhao Y; et al. TAFs contributes the function of PTPN2 in colorectal carcinogenesis through activating JAK/STAT signaling pathway. Am J Cancer Res 2021 Jun 15;11(6):3085-3097. (PubMed: 34249446) [IF=5.177]

9). Shi C;Weng M;Zhu H;Guo Y;Xu D;Jin H;Wei B;Cao Z; et al. NUDCD1 knockdown inhibits the proliferation, migration, and invasion of pancreatic cancer via the EMT process. Aging (Albany NY) 2021 Jul 29;13(14):18298-18309. (PubMed: 34325402) [IF=4.831]

10). Li G;Chen S;Zhang Y;Xu H;Xu D;Wei Z;Gao X;Cai W;Mao N;Zhang L;Li S;Yang F;Liu H;Li S; et al. Matrix stiffness regulates α-TAT1/Ac-α-Tub and promotes silica-induced epithelial-mesenchymal transition via DNA damage. J Cell Sci 2020 Dec 11;jcs.243394. (PubMed: 33310909) [IF=4.573]

11). Liu X et al. Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells. Front Pharmacol 2020 Apr 17;11:495 (PubMed: 32362830) [IF=4.225]

12). Li X et al. Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice. Front Pharmacol 2019 Sep 13;10:1021 (PubMed: 31572194) [IF=4.225]

13). Xu PP et al. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide. Sci Rep 2017 Aug 7;7(1):7433 (PubMed: 28785100) [IF=3.998]

Application: IF/ICC    Species:mouse;    Sample:Not available

Lenalidomide (1μM) inhibited JAM-A-transfected cell invasion (B) and EMT (C).

14). Li H et al. MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 Oct;47(4):1379-92 (PubMed: 26323677) [IF=3.899]

Application: WB    Species:human;    Sample:A549 cells

Figure 3. A549/DDP and A549/PTX cells showed molecular and morphological changes that were consistent with EMT. (A) microscopy at x200 magnification was used to assess cell morphology. The A549 cells (parental cells) had an epithelioid, rounded cobblestone appearance and there was limited formation of pseudopodia. A549/PTX and A549/DDP cells exhibited a spindle-shaped morphology and an increased formation of pseudopodia, indicating a loss of cell polarity. (B) E-cadherin, β-catenin, vimentin, MMP-2 and MMP-9 which are EMT-related proteins, were assessed in terms of expression levels. EMT-related transcription factors (Snail, Slug, Twist and ZEB1) were measured in A549/PTX and A549/DDP cells using western blot analysis. (C) The expression changes were confirmed at the mRNA level by qRT-PCR. Expression was standardized to the expression of GAPDH and normalized to 1.0 in the parental cells (compared with the parental A549 cells, means ± SEM, n=3, * P<0.05)

15). Gao R;Ren L;Zhou Y;Wang L;Xie Y;Zhang M;Liu X;Ke S;Wu K;Zheng J;Liu X;Chen Z;Liu L; et al. Recurrent non-severe hypoglycemia aggravates cognitive decline in diabetes and induces mitochondrial dysfunction in cultured astrocytes. Mol Cell Endocrinol 2021 Apr 15;526:111192. (PubMed: 33545179) [IF=3.871]

16). Jing Y;Gao B;Han Z;Xia L;Xin S; et al. The protective effect of HOXA5 on carotid atherosclerosis occurs by modulating the vascular smooth muscle cell phenotype. Mol Cell Endocrinol 2021 Jun 11;111366. (PubMed: 34126188) [IF=3.871]

17). Liu Y;Huang J;Yu N;Wei S;Liu Z; et al. Involvement of WNT2 in trophoblast cell behavior in preeclampsia development. Cell Cycle 2020 Aug 11;1-9. (PubMed: 32779546) [IF=3.699]

18). Chen Z et al. Lower Expression of Gelsolin in Colon Cancer and Its Diagnostic Value in Colon Cancer Patients. J Cancer 2019 Jan 30;10(5):1288-1296 (PubMed: 30854138) [IF=3.565]

19). Zhao W et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer. Cancer Med 2019 Jan 11 (PubMed: 30632714) [IF=3.491]

20). An Q;Liu T;Wang MY;Yang YJ;Zhang ZD;Liu ZJ;Yang B; et al. KRT7 promotes epithelial‑mesenchymal transition in ovarian cancer via the TGF‑β/Smad2/3 signaling pathway. Oncol Rep 2020 Dec 8;45(2):481-492. (PubMed: 33416175) [IF=3.417]

21). Zhang Q;Yang X;Luo L;Ma X;Jiao W;Li B;Zhang M;Zhao K;Niu H; et al. Targeted p21 activation by a new double stranded RNA suppresses human prostate cancer cells growth and metastasis. Am J Transl Res 2020 Aug 15;12(8):4175-4188. (PubMed: 32913496) [IF=3.375]

22). Liu YR et al. Selenium-lentinan inhibits tumor progression by regulating epithelial-mesenchymal transition. Toxicol Appl Pharmacol 2018 Dec 1;360:1-8 (PubMed: 30240696) [IF=3.347]

23). Zhao M;Sun Y;Gao Z;Cui H;Chen J;Wang M;Wang Z; et al. Gigantol Attenuates the Metastasis of Human Bladder Cancer Cells, Possibly Through Wnt/EMT Signaling. Onco Targets Ther 2020 Nov 4;13:11337-11346. (PubMed: 33177841) [IF=3.337]

24). Liu H et al. Autophagy contributes to hypoxia-induced epithelial to mesenchymal transition of endometrial epithelial cells in endometriosis. Biol Reprod 2018 May 31 (PubMed: 29860279) [IF=3.322]

25). Ma G;Li G;Gou A;Xiao Z;Xu Y;Song S;Guo K;Liu Z; et al. Long non-coding RNA ELFN1-AS1 in the pathogenesis of pancreatic cancer. Ann Transl Med 2021 May;9(10):877. (PubMed: 34164511) [IF=3.297]

26). Lu T;Ma K;Zhan C;Yang X;Shi Y;Jiang W;Wang H;Wang S;Wang Q;Tan L; et al. Downregulation of long non-coding RNA LINP1 inhibits the malignant progression of esophageal squamous cell carcinoma. Ann Transl Med 2020 Jun;8(11):675. (PubMed: 32617295) [IF=3.297]

27). Wang HF;Ma JX;Shang QL;An JB;Chen HT; et al. Crocetin inhibits the proliferation, migration and TGF-β 2-induced epithelial-mesenchymal transition of retinal pigment epithelial cells . Eur J Pharmacol 2017 Nov 15;815:391-398. (PubMed: 28970011) [IF=3.263]

Application: WB    Species:human;    Sample:ARPE-19

Figure 4. Crocetin inhibits TGF-β2-induced EMT. After 1 h of pretreatment with crocetin, ARPE-19 cells used for EMT assay were stimulated with or without recombinant human TGF-β2 for up to 24 or 48 h. (A) Phase contrast photomicrographs of confluent cultures of cells were captured after treatment for 48 h. Scale bar: 200 μm. (B) Western blot analysis levels of of ZO-1, E-cadherin, Vimentin, α-SMA and the housekeeping protein GAPDH in the lysates of ARPE-19 cells after treatment for 48 h. *P< 0.05, **P< 0.01, ***P< 0.001. The data are presented as the mean ± S.D. (n = 3/group).

28). Wang HF;Ma JX;Shang QL;An JB;Chen HT; et al. Crocetin inhibits the proliferation, migration and TGF-β 2-induced epithelial-mesenchymal transition of retinal pigment epithelial cells . Eur J Pharmacol 2017 Nov 15;815:391-398. (PubMed: 28970011) [IF=3.263]

29). Du Y et al. Estradiol promotes EMT in endometriosis via MALAT1/miR200s sponge function. Reproduction 2018 Nov 1 (PubMed: 30500775) [IF=3.206]

30). Jiang M;Lash GE;Zeng S;Liu F;Han M;Long Y;Cai M;Hou H;Ning F;Hu Y;Yang H; et al. Differential expression of serum proteins before 20 weeks gestation in women with hypertensive disorders of pregnancy: A potential role for SH3BGRL3. Placenta 2020 Nov 14;104:20-30. (PubMed: 33217630) [IF=3.177]

31). Liu C;Zhou X;Pan Y;Liu Y;Zhang Y; et al. Pyruvate carboxylase promotes thyroid cancer aggressiveness through fatty acid synthesis. BMC Cancer 2021 Jun 22;21(1):722. (PubMed: 34158007) [IF=3.150]

32). Chen G et al. SOSTDC1 inhibits bone metastasis in non-small cell lung cancer and may serve as a clinical therapeutic target. Int J Mol Med 2018 Oct 10 (PubMed: 30320379) [IF=3.098]

33). Shao Q et al. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition. Gene 2018 Apr 30;652:48-58 (PubMed: 29427737)

34). Hou F et al. Yi Ai Fang, a traditional Chinese herbal formula, impacts the vasculogenic mimicry formation of human colorectal cancer through HIF-1α and epithelial mesenchymal transition. BMC Complement Altern Med 2016 Nov 2;16(1):428 (PubMed: 27806701)

Application: WB    Species:human;    Sample:Not available

Fig. 2 YAF influences HIF-1α and EMT expression analysis in HCT-116 cell lines. a. Cells were incubated for 48 h in YAF. The level of HIF-1α, Clau-4, E-cd and VIM mRNA were found. b HCT-116 cells were incubated with YAF for 48 h. The level of HIF-1α, Clau-4, E-cd and VIM protiens were found. *P < 0.05. Results are folden change ± SE of at least three independent experiments

Application: IHC    Species:human;    Sample:Not available

35). Wang X et al. Effects of endometrial stem cell transplantation combined with estrogen in the repair of endometrial injury. Oncol Lett 2018 Jul;16(1):1115-1122 (PubMed: 29963188)

36). Gong J et al. Krüppel‑like factor 4 ameliorates diabetic kidney disease by activating autophagy via the mTOR pathway. Mol Med Rep 2019 Oct;20(4):3240-3248 (PubMed: 31432191)

37). Yan JD et al. Expression and prognostic significance of VEGFR-2 in breast cancer. Pathol Res Pract 2015 Jul;211(7):539-43 (PubMed: 25976977)

38). Duan Z et al. Endothelin-1-induced expression of α-smooth muscle actin in human myometrial fibroblasts. J Obstet Gynaecol Res 2018 Mar;44(3):540-546 (PubMed: 29271089)

39). Duan Z et al. Endothelin-1-induced expression of α-smooth muscle actin in human myometrial fibroblasts. J Obstet Gynaecol Res 2018 Mar;44(3):540-546 (PubMed: 29271089)

40). Ai XY et al. Sesquiterpene binding Gly-Leu-Ser/Lys-"co-adaptation pocket" to inhibit lung cancer cell epithelial-mesenchymal transition. Oncotarget 2017 Jul 26;8(41):70192-70203 (PubMed: 29050271)

Application: IHC    Species:human,mouse;    Sample:Not available

Figure 6: Effect of PTL on p-ERK 2, NF-κB, Snail, and EMT protein levels. Brown or yellow staining was observed in the cytoplasmor nucleus. (A and C) Representative photographs of treated and untreated cells. PTL treatment reduced p-ERK 2, NF-κB, and Snail staining compared with sections obtained from control mice. (B and D) Representative photographs of treated and untreated cells. PTL treatment increased E-cadherin and Occludin staining and reduced Vimentin and N-cadherin staining compared with sections obtained from control mice. Each experiment was performed in triplicate. Results show the means of the three experiments, and the error bars represent standard deviation (*P < 0.05 and **P < 0.01).

Application: IF/ICC    Species:human,mouse;    Sample:Not available

41). Li XH et al. Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-κB/Snail signaling pathway. Respir Res 2018 Jun 5;19(1):111 (PubMed: 29871641)

42). Zhou P et al. Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis. J Exp Clin Cancer Res 2017 Sep 2;36(1):115 (PubMed: 28865485)

Application: WB    Species:mouse;    Sample:B16F10

Fig. 5 The expression of p-PKCζ, p-cofilin and COX-2 after combined treatment of J-4 and Celecoxib. (a) Western blotting images of p-cofilin and COX-2 in B16-F10 cells with various treatments for 24 h. (b) Western blotting images of p-cofilin and COX-2 in A375 cells with various treatments for 24 h. (c) Relative mRNA level of PKCζ and COX-2 determined via RT-PCR. (d) The expression of EMT markers, E-Cadherin and Vimentin, and MMP-2/MMP-9 was affected in B16-F10 and A375 cells after various treatments for 24 h. J-4: 25 μM; Celecoxib: 25 μM. * P < 0.05; ** P < 0.01

43). et al. The role of long noncoding RNA AL161431. 1 in the development and progression of pancreatic cancer.

44). et al. RAC1/miR-3613/RAC1 feedback loop contributes to ovarian cancer progression.

45). et al. LncRNA HOXC-AS3 Promotes Epithelial-tomesenchymal Transition through Decreasing the Expression of FBXL17 in Cervical Squamous Cell Carcinoma.

46). et al. A novel UV-curable extravascular stent to prevent restenosis of venous grafts.

47). Nie J;Liu Y;Sun C;Zheng J;Chen B;Zhuo J;Su Z;Lai X;Chen J;Zheng J;Li Y; et al. Effect of supercritical carbon dioxide fluid extract from Chrysanthemum indicum Linné on bleomycin-induced pulmonary fibrosis. BMC Complement Med Ther 2021 Sep 25;21(1):240. (PubMed: 34563177)

48). et al. High-dose vitamin D3 c ameliorates renal fibrosis by vitamin D receptor activation and inhibiting TGF-β1/Smad3 signaling pathway in 5/6 nephrectomized rats.

49). Yang J et al. miR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition. J Gastroenterol Hepatol 2017 Dec;32(12):1966-1974 (PubMed: 28370348)

Application: WB    Species:rat;    Sample:Not available

Effects of null-MVs and miR-200b-MVs administration on protein expression in TGFb-Indeced EMT.

50). et al. Platelet-Rich Plasma Improves Pregnancy Rate and Repairs Endometrial Injury in Patients with Repeated Implantation Failure.

51). et al. IGF-1 Promotes Epithelial-Mesenchymal Transition of Lens Epithelial Cells That is Conferred by miR-3666 Loss.

52). et al. LncRNA HOXC-AS3 Promotes Epithelial-to-mesenchymal Transition through Decreasing the Expression of FBXL17 in Cervical Squamous Cell Carcinoma.

53). et al. RECQL4 regulates DNA damage response and redox homeostasis in esophageal cancer.

54). et al. LOXL 2 Promotes The Epithelial–Mesenchymal Transition And Malignant Progression Of Cervical Cancer.

55). et al. Adenomyosis-derived extracellular vesicles endow endometrial epithelial cells with an invasive phenotype through epithelial-mesenchymal transition.

56). Zhao L;Bi M;Zhang H;Shi M; et al. Downregulation of NEAT1 Suppresses Cell Proliferation, Migration, and Invasion in NSCLC Via Sponging miR-153-3p. Cancer Biother Radiopharm 2020 May 7. (PubMed: 32380843)

No comment
Total 0 records, divided into1 pages. First Prev Next Last

Submit Review

Support JPG, GIF, PNG format only
Catalog Number :

(Blocking peptide available as AF7013-BP)

Price/Size :

Tips: For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).

Function :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.

Format and storage :

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions :

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

High similarity Medium similarity Low similarity No similarity
P08670 as Substrate
Site PTM Type Enzyme
S2 Phosphorylation
T3 Phosphorylation
R4 Methylation
S5 Phosphorylation P17252 (PRKCA)
S7 O-Glycosylation
S7 Phosphorylation P17252 (PRKCA) , Q96GD4 (AURKB) , Q02156 (PRKCE) , P17612 (PRKACA)
S8 Phosphorylation P17252 (PRKCA)
S9 Phosphorylation P17252 (PRKCA)
S10 Phosphorylation P17252 (PRKCA)
Y11 Phosphorylation
R12 Methylation
R13 Methylation
T20 Phosphorylation
S22 Phosphorylation
R23 Methylation
S25 Phosphorylation P17252 (PRKCA) , Q96GD4 (AURKB) , P17612 (PRKACA)
S26 Phosphorylation Q13153 (PAK1) , P17252 (PRKCA) , Q13177 (PAK2)
S27 Phosphorylation
R28 Methylation
S29 Phosphorylation
Y30 Phosphorylation
T32 Phosphorylation
T33 O-Glycosylation
T33 Phosphorylation
S34 O-Glycosylation
S34 Phosphorylation P17252 (PRKCA)
T35 Phosphorylation
R36 Methylation
T37 Phosphorylation
Y38 Phosphorylation
S39 Phosphorylation P49137 (MAPKAPK2) , Q13177 (PAK2) , P17612 (PRKACA) , O75116 (ROCK2) , P31749 (AKT1) , Q13153 (PAK1) , Q96GD4 (AURKB) , P17252 (PRKCA)
S42 Phosphorylation P17252 (PRKCA)
R45 Methylation
S47 Phosphorylation P17612 (PRKACA) , Q96GD4 (AURKB)
T48 Phosphorylation
S49 Phosphorylation
R50 Methylation
S51 Phosphorylation Q13177 (PAK2) , Q13153 (PAK1) , P49137 (MAPKAPK2)
Y53 Phosphorylation
S55 O-Glycosylation
S55 Phosphorylation P24941 (CDK2) , P06493 (CDK1)
S56 Phosphorylation P78527 (PRKDC) , P06493 (CDK1) , P49137 (MAPKAPK2) , Q13153 (PAK1) , P24941 (CDK2) , Q00535 (CDK5)
Y61 Phosphorylation
T63 Phosphorylation
R64 Methylation
S65 Phosphorylation Q96GD4 (AURKB)
S66 Phosphorylation Q96GD4 (AURKB) , Q13177 (PAK2) , Q13153 (PAK1)
R69 Methylation
R71 Methylation
S72 Phosphorylation P17612 (PRKACA) , Q96GD4 (AURKB) , Q13464 (ROCK1) , O75116 (ROCK2)
S73 Phosphorylation Q13177 (PAK2) , Q96GD4 (AURKB) , P17612 (PRKACA) , Q13153 (PAK1)
S83 Phosphorylation Q13557 (CAMK2D) , Q9UQM7 (CAMK2A) , P49137 (MAPKAPK2) , P53350 (PLK1)
S87 Phosphorylation Q96GD4 (AURKB)
K97 Ubiquitination
T99 Phosphorylation
T101 Phosphorylation
K104 Acetylation
K104 Ubiquitination
R113 Methylation
Y117 Phosphorylation
K120 Acetylation
K120 Methylation
K120 Ubiquitination
K129 Acetylation
K129 Ubiquitination
K139 Acetylation
K139 Ubiquitination
K143 Ubiquitination
S144 Phosphorylation
Y150 Phosphorylation
R158 Methylation
K168 Acetylation
K168 Ubiquitination
R184 Methylation
K188 Ubiquitination
T202 Phosphorylation
S205 Phosphorylation
S214 Phosphorylation
K223 Ubiquitination
S226 Phosphorylation
K235 Acetylation
K235 Ubiquitination
K236 Acetylation
K236 Ubiquitination
S261 Phosphorylation
K262 Ubiquitination
T266 Phosphorylation
Y276 Phosphorylation
S278 Phosphorylation
K282 Acetylation
K282 Ubiquitination
Y291 Phosphorylation
K292 Acetylation
K292 Ubiquitination
K294 Acetylation
K294 Ubiquitination
S299 Phosphorylation
R310 Methylation
K313 Acetylation
K313 Sumoylation
K313 Ubiquitination
S316 Phosphorylation
T317 Phosphorylation
S325 Phosphorylation
T327 Phosphorylation
C328 S-Nitrosylation
K334 Acetylation
K334 Ubiquitination
T336 Phosphorylation
S339 Phosphorylation
Y358 Phosphorylation
T361 Phosphorylation
K373 Acetylation
K373 Ubiquitination
R381 Methylation
Y383 Phosphorylation
Y400 Phosphorylation
R401 Methylation
K402 Acetylation
K402 Sumoylation
K402 Ubiquitination
S409 Phosphorylation
R410 Methylation
S412 Phosphorylation
S419 Phosphorylation
S420 Phosphorylation
T426 Phosphorylation
S430 Phosphorylation P78527 (PRKDC)
T436 Phosphorylation
S438 Phosphorylation
K439 Acetylation
K439 Ubiquitination
T441 Phosphorylation
K445 Acetylation
K445 Methylation
K445 Sumoylation
K445 Ubiquitination
T446 Phosphorylation
T449 Phosphorylation
T458 Phosphorylation P00540 (MOS)
S459 Phosphorylation P78527 (PRKDC) , P53350 (PLK1) , P00540 (MOS)
IMPORTANT: For western blots, incubate membrane with diluted antibody in 5% w/v milk , 1X TBS, 0.1% Tween®20 at 4°C with gentle shaking, overnight.

To Top